Marker Therapeutics, Inc. (MRKR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 861,184 | - | 1,926,020 | 1,169,236 |
| Research and development | 4,177,054 | - | 3,471,216 | 2,335,430 |
| General and administrative | 945,163 | - | 854,677 | 1,141,871 |
| Total operating expenses | 5,122,217 | - | 4,325,893 | 3,477,301 |
| Loss from operations | -4,261,033 | - | -2,399,873 | -2,308,065 |
| Interest income | 128,025 | - | 91,681 | 115,388 |
| Other income | 117,444 | - | - | - |
| Loss from continuing operations before income taxes | - | - | - | - |
| Net loss from continuing operations | - | - | -2,308,192 | -2,192,677 |
| Net loss | -4,015,564 | - | -2,308,192 | -2,192,677 |
| Earnings per share, basic | -0.29 | -0.4 | -0.26 | -0.25 |
| Earnings per share, diluted | -0.29 | -0.4 | -0.26 | -0.25 |
| Weighted average number of shares outstanding, basic | 13,956,562 | 11,106,027 | 8,923,170 | 8,918,233 |
| Weighted average number of shares outstanding, diluted | 13,956,562 | 11,106,027 | 8,923,170 | 8,918,233 |